Trial Profile
Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dofetilide (Primary) ; Diltiazem; Lidocaine; Mexiletine; Moxifloxacin
- Indications Atrial fibrillation; Atrial flutter
- Focus Pharmacodynamics
- 16 Dec 2014 New trial record